These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3203045)

  • 1. The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.
    Francis JL; Roath OS; Challenor VF; Waller DG
    Br J Clin Pharmacol; 1988 Jun; 25(6):751-4. PubMed ID: 3203045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nisoldipine in primary Raynaud's phenomenon.
    Challenor VF; Waller DG; Francis DA; Francis JL; Mani R; Roath S
    Eur J Clin Pharmacol; 1987; 33(1):27-30. PubMed ID: 3691593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.
    Gjørup T; Hartling OJ; Kelbaek H; Nielsen SL
    Eur J Clin Pharmacol; 1986; 31(4):387-9. PubMed ID: 3816916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibition of platelet aggregation and thromboxane formation by the calcium antagonist nisoldipine following a single oral dose of 10 mg. A double-blind study in healthy probands].
    Schrör K; Latta G; Darius H; Klaus W; Ziegler R
    Klin Wochenschr; 1985 Jan; 63(1):16-9. PubMed ID: 3838352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal platelet aggregation in patients with Raynaud's phenomenon.
    Biondi ML; Marasini B
    J Clin Pathol; 1989 Jul; 42(7):716-8. PubMed ID: 2760232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.
    Jones CR; Pasanisi F; Elliott HL; Reid JL
    Br J Clin Pharmacol; 1985 Sep; 20(3):191-6. PubMed ID: 2994701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.
    Jeremy JY; Barradas MA; Mikhailidis DP; Dandona P
    Br J Clin Pharmacol; 1986 Aug; 22(2):201-2. PubMed ID: 3756069
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation.
    Malamet R; Wise RA; Ettinger WH; Wigley FM
    Am J Med; 1985 Apr; 78(4):602-8. PubMed ID: 3157318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.
    Ettinger WH; Wise RA; Schaffhauser D; Wigley FM
    Am J Med; 1984 Sep; 77(3):451-6. PubMed ID: 6540986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcium antagonists for the treatment of Raynaud's phenomenon].
    Müller-Bühl U; Diehm C; Scheuermann W; Mörl H
    Dtsch Med Wochenschr; 1983 Nov; 108(47):1795-7. PubMed ID: 6357692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.
    Marasini B; Biondi ML; Bianchi E; Dell'Orto P; Agostoni A
    Eur J Clin Pharmacol; 1988; 35(4):419-21. PubMed ID: 3197751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory effects of nifedipine in Raynaud's phenomenon.
    Hawkins SJ; Black CM; Hall ND; McGregor A; Ring EF; Maddison PJ
    Rheumatol Int; 1986; 6(2):85-8. PubMed ID: 3764307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome.
    Lau CS; Khan F; McLaren M; Bancroft A; Walker M; Belch JJ
    Rheumatol Int; 1991; 11(4-5):163-8. PubMed ID: 1838424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
    Corbin DO; Wood DA; Macintyre CC; Housley E
    Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects.
    Pasanisi F; Meredith PA; Reid JL
    Eur J Clin Pharmacol; 1985; 29(1):21-4. PubMed ID: 4054203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of platelet function in patients with Raynaud's syndrome.
    Hutton RA; Mikhailidis DP; Bernstein RM; Jeremy JY; Hughes GR; Dandona P
    J Clin Pathol; 1984 Feb; 37(2):182-7. PubMed ID: 6229551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study.
    White CJ; Phillips WA; Abrahams LA; Watson TD; Singleton PT
    Am J Med; 1986 Apr; 80(4):623-5. PubMed ID: 3515931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo platelet studies following oral nisoldipine in normotensive insulin-dependent diabetics and non-diabetic controls.
    Hendra TJ; Oughton J; Jeremy JY; Smith CC; Betteridge DJ; Dandona P; Yudkin JS
    Diabetes Res; 1988 Jul; 8(3):117-22. PubMed ID: 2976336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet Aggregation in Primary Raynaud's Phenomenon and the Effect of Enalapril Administration.
    Dowie A; Francis JL; Roath OS; Challenor VF; Waller DG
    Platelets; 1990; 1(1):25-7. PubMed ID: 21043982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.